Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

neuroendocrine carcinoma (NEC) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

neuroendocrine carcinoma

MONDO:0002120

Also known as:NECneuroendocrine cancer

Find Clinical TrialsTrials

Overview

A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin. The neoplastic cells are often round and form clusters or trabecular sheets. Representative examples are small cell carcinoma, large cell neuroendocrine carcinoma, and Merkel cell carcinoma.

TreatmentsNo approved treatments · 5 in pipeline

Clinical Trials113 registered · 31 recruiting

Patient Orgs1 organizations · The Healing Net Foundation

Diagnosis

Biomarker and diagnostic research for neuroendocrine carcinoma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for neuroendocrine carcinoma. An additional 5 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for neuroendocrine carcinoma, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for neuroendocrine carcinoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

113 clinical trials registered, 31 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE4, 4 PHASE3, 48 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06176989](https://clinicaltrials.gov/study/NCT06176989)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

The Healing Net FoundationPrimary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

Questions for Your Care Team

→Are any of the 113 active clinical trials a good fit for my situation?
→With 5 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with The Healing Net Foundation and other patient organizations for support?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	123	32%
Research summaries	86	22%
Laboratory research	50	13%
Disease patterns and progression	39	10%
Clinical study results	36	9%
Testing and diagnosis research	32	8%
Other research	9	2%
New treatment approaches	9	2%

Kisho

neuroendocrine carcinoma

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms.

neuroendocrine carcinoma

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms.